News Hub | News Direct

All Industries


Article thumbnail News Release

Trident Royalties reports strong quarterly performance and strategic asset developments

Trident Royalties PLC

Trident Royalties PLC (AIM:TRR, OTCQX:TDTRF) CEO Adam Davidson joined Proactive's Stephen Gunnion with details of the company's performance for the quarter ended 31 March 2024. Royalty income approached amounted to US$2.98 million, with a notable performance from its gold offtake portfolio, especially during March which continued into the second quarter due to favourable gold prices. Davidson highlighted seasonal production variations, with reduced outputs in the first quarter generally compensated by higher gold prices. Significant developments include the full acquisition of Greenstone mine by Equinox Gold, anticipated to produce up to 400,000oz annually for the first five years, and Trident's gold offtake from this mine is expected to contribute substantially to revenue. Davidson also touched on a production expansion at the Blyvoor Gold mine, which could significantly boost Trident's royalties from increased production targets. Additionally, the US Department of Energy's conditional commitment to loan $2.26 billion for the Thacker Pass lithium development was a crucial milestone, supporting the construction of one of the world's largest lithium deposits, and promising long-term revenue contributions to Trident. Davidson also discussed the sale of Trident's Australian gold royalty portfolio, which was a strategic move to optimize the asset mix and reinvest capital into new acquisitions, enhancing the company's growth trajectory. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 08, 2024 08:56 AM Eastern Daylight Time

Video
Article thumbnail News Release

Aclara Resources awards Carina Module pre-feasibility study to Hatch

Aclara Resources Inc

Aclara Resources Inc (TSX:ARA, OTC:ARAAF) chief operating officer Barry Murphy joined Proactive's Stephen Gunnion with news that the company has contracted global multidisciplinary consultancy firm Hatch to complete the prefeasibility study (PFS) for the Carina Module rare earths project in Brazil. Murphy cited Hatch's extensive experience and good fit with Aclara's team as the primary reasons for the choice. The pre-feasibility study, a crucial step following the issuance of a preliminary economic assessment earlier this year, will focus on various trade-offs concerning the availability of resources like power and water. The study is expected to conclude around mid-next year, after which Aclara plans to transition to a feasibility study. The pre-feasibility study results will not be made public as Aclara aims to expedite the process towards the feasibility phase. Following the completion of the feasibility study, Aclara anticipates releasing a NI 43-101 compliant technical report by mid-2026. In the short term, Murphy said Aclara is preparing to issue updates following a new drilling campaign that expanded the resource at depth. Further, the company plans to relocate its pilot plant from Chile to Brazil to facilitate tests relevant to the project's pre-feasibility phase. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

May 08, 2024 08:53 AM Eastern Daylight Time

Video
Article thumbnail News Release

With The Cryptocurrency Market Historically Tumultuous, Regulated Futures Brokers Like EdgeClear May Offer More Security Than Their Spot Counterparts

EdgeClear

By Austin DeNoce, Benzinga The cryptocurrency market has been a rollercoaster of innovation and growth, but it's not without its share of pitfalls. National Futures Association (NFA), the self-regulatory organization for the U.S. derivatives industry, does not have regulatory oversight of the spot virtual currency. This lack of regulation for many crypto exchanges has led to significant risks for investors, including the insolvency of major platforms often resulting in frozen or lost funds. This situation is akin to the shock of finding one's bank account locked, yet it stems from insufficient oversight indirectly permitting risky operational practices that can lead to liquidity crises or shutdowns on the basis of regulatory non-compliance. Advantages Of Futures Exchanges Unlike the largely unregulated crypto spot exchanges, futures exchanges offer a secure and stable trading environment underpinned by regulatory bodies like the Commodity Futures Trading Commission (CFTC). These platforms enforce stringent safeguards to protect customer funds, ensuring transparency, centralized trading and minimized counterparty risk. As institutions under the watchful eye of major regulatory bodies, futures exchanges are required to follow strict financial protocols, including maintaining sufficient capital reserves and robust security measures to protect investor assets. A study by Liangfei Qiu of the University of Florida highlights the benefits of regulation in the cryptocurrency market, demonstrating that stricter regulations lead to more efficient markets. It points out the risks of unregulated cryptocurrencies, such as price manipulation and lack of crucial information, and advocates for investments in platforms that offer vetted information to protect investors and enhance market efficiency. The EdgeClear Advantage Trading on regulated futures exchanges such as those used by EdgeClear can grant investors a distinct set of advantages, offering them an edge in precision and risk management when venturing into the cryptocurrency market. By leveraging micro products for Bitcoin and Ether, traders can potentially enjoy a level of exposure that is fine-tuned to their trading strategies and risk profiles. These micro products are sized at 1/10 of their respective tokens, allowing for a more targeted approach to trading that caters to both short-term and long-term investment outlooks across a variety of strategies, from market neutral to directional. Below are some key advantages of trading cryptocurrency futures with EdgeClear: ● Enhanced trading precision: Micro products allow for detailed control over exposure levels to bitcoin and ether that enable more tailored trading strategies. ● Capitalizing on market downturns: With futures trading, you have the flexibility to either sell or buy into the market, enabling you to seize opportunities presented by downward price movements. ● Flexible risk management: The granularity of micro contracts assists in adjusting risk profiles with greater accuracy. ● Regulatory safeguards: Trading within a CFTC-regulated marketplace such as the CME Group ensures transparency, centralized trading and reduced counterparty risk. ● High-quality market data: Access to the CME CF Cryptocurrency Benchmarks, which provide regulated reference rates and spot price indices ensures high-quality pricing information. ● Around-the-clock trading: The convenience of nearly 24-hour trading on the CME Globex platform allows for global market access. ● Potential tax benefits: Profitable futures trades are taxed on a 60/40 basis: 60% of gains are taxed at the long-term capital gains rate, and 40% of gains are taxed at the short-term capital gains rate like ordinary income. ● Cost efficiency: Competitive pricing with discounted exchange fee pricing through July 31, 2024 makes trading more accessible and relatively lower in cost than spot prices and spreads.. EdgeClear's partnership with platforms like the CME Group Inc. (NASDAQ: CME) and its use of the CME CF Cryptocurrency Benchmarks represent a commitment to offering a trading environment that is flexible, precise and grounded in a framework that prioritizes the security and reliability of market data. These elements combine to create an appealing trading experience that is aligned with the best practices of the industry to help ensure traders can navigate the crypto markets with more confidence. “CME Group is a leading regulated venue for cryptocurrency derivatives. Our market-leading suite of benchmark crypto futures and options provide a way for investors to gain crypto exposure on a regulated market with established financial safeguards for more transparent and efficient risk management,” said Giovanni Vicioso, Global Head of Cryptocurrency Products at CME Group “From a trading perspective, I see a distinct advantage to trading MBT over spot Bitcoin, for example, for several reasons: 1) The product is cleared on a central exchange, so the volume data provides for a better technical read on supply and demand, 2) I’m able to take advantage of the preferential tax treatment afforded to derivatives in the U.S., 3) There are no hidden transaction fees, such as gas fees; my cost structure is very clear, 4) I can use my favorite trading platform such as EdgeProX and don’t need to open another account or learn a new platform to trade it. Trading already carries significant risk, wondering about the safety of my wallet or the solvency of the exchange are additional risks I don’t need to worry about as much with futures,” said Morad Askar, CEO of EdgeClear and licensed professional trader. Embracing Regulation For A More Secure Trading Experience The tumultuous landscape of cryptocurrency trading has probably been the best argument for regulation. Although adherence to regulatory standards is technically about compliance, it’s a critical measure for protecting investors and ensuring market efficiency. The benefits of trading on regulated futures exchanges, such as platforms like EdgeClear, highlight the value of much-needed security, transparency and reliability in the cryptocurrency market. However, it is crucial to acknowledge that the price movement and profitability of virtual currency derivative trading are susceptible to the same risk factors that influence the underlying spot markets. For investors seeking to navigate the complexities of cryptocurrency trading, regulated futures exchanges can offer a more secure and efficient pathway to engaging with the digital asset economy. Featured photo by Art Rachen on Unsplash. A forward-thinking futures broker. Led by industry experts who understand the complexities of trading, Edge Clear combines the best of technology, service and risk control. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. This post is part of a paid marketing agreement. Contact Details Max Timmins max@edgeclear.com

May 08, 2024 08:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

RC365 Holding CEO Michael Law discusses rapid growth and future plans

RC365 Holding PLC

RC365 Holding PLC (LSE:RCGH) has made significant progress in 2024, according to CEO Michael Law, in an interview with Proactive's Stephen Gunnion. The company has transitioned 100% of its office operations, including finance, IT, and customer service, to Malaysia and Indonesia, hiring over ten new staff members in the region. RC365 has also won substantial contracts in Japan and secured a £100,000 grant from the Hong Kong Trade and Industry Department to further expand operations in Malaysia. Furthermore, RC365 agreed to £4 million in loan notes to fund upgrades and enhance its platform, focusing on services like virtual banking. The company's presence in Japan has particularly grown with a contract worth £600,000 aimed at integrating their services into local societal structures. Law highlighted the company’s strong financial position and pipeline, which includes government grants and significant contracts, enabling sustained development and low-cost operations. As 2024 progresses, RC365's focus will be on upgrading its platform to support new functionalities such as virtual banking and enhanced payment options. The company also plans to leverage AI for marketing strategies, specifically for online shopping promotions. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 08, 2024 08:37 AM Eastern Daylight Time

Video
Article thumbnail News Release

Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office

Poolbeg Pharma PLC

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief legal officer John McEvoy joins Proactive's Stephen Gunnion with news that POLB 001's Immuno-modulator II has received the fully granted patent from the US Patent Office. McEvoy explained the patent encompasses a class of drugs for treating and preventing hypercytokinemia (cytokine storms) in patients triggered by an immune response, applicable across multiple disease indications. The granted patent further solidifies Poolbeg Pharma's robust intellectual property portfolio for POLB 001, potentially increasing the asset's value and making it more attractive to potential partners. McEvoy highlighted the company's ongoing efforts to strengthen and expand their IP portfolio, noting existing patents covering p38 MAP kinase inhibitors for influenza treatment and hypercytokinemia. Additional patents have been filed, particularly focusing on cancer immunotherapy applications of POLB 001. The company has also applied for patents concerning dosage regimens based on results from their recent LPs trial, aiming to protect innovations and maintain a competitive edge in the pharmaceutical market. This strategic IP protection is crucial for safeguarding the company's products and ensuring shareholder value, particularly as they seek partnerships to further develop POLB 001. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 08, 2024 08:32 AM Eastern Daylight Time

Video
Article thumbnail News Release

Electric Guitar debuts on AIM with big plans following 3radical acquisition

Electric Guitar PLC

Electric Guitar PLC (AIM:ELEG) CEO John Regan spoke to Proactive's Stephen Gunnion following the company's listing on London's AIM market following the reverse takeover of 3radical. Regan emphasized Electric Guitar's "buy and build" strategy, which involves acquiring complementary businesses to enhance their market position. Despite the challenging market conditions, the company managed to complete its IPO on AIM, a testament to its team's strength and compelling business proposition. 3radical specialises in collecting first-party data—a valuable asset in today's privacy-focused advertising market. This acquisition marks Electric Guitar's entry into the technical side of the advertising industry, responding to significant shifts such as reduced accessibility to third-party data due to privacy regulations. 3radical's technology allows for real-time adaptation to user input, which is unique in the market and enhances the relevancy of advertising. Furthermore, Regan said 3radical's extensive database of engagement events offers potential for advanced machine learning applications, positioning Electric Guitar to exploit AI technologies effectively. Looking forward, Regan outlined plans to enhance sales and marketing efforts, particularly focusing on exploiting the newly acquired technologies and data assets from 3radical. Electric Guitar is also preparing to expand its portfolio by acquiring additional complementary businesses, aiming to leverage these new assets to secure a competitive advantage in a rapidly evolving market. Contact Details Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

May 08, 2024 08:24 AM Eastern Daylight Time

Video
Article thumbnail News Release

Faron Pharmaceuticals' new CEO Dr Juho Jalkanen sets bold vision for 2024

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Limited (AIM:FARN) new CEO Dr Juho Jalkanen joined Proactive's Stephen Gunnion with his vision for the company. The founding member and former chief operating officer of Faron said one of his priorities is to meet with the US Food & Drug Administration earlier than planned in the hope of fast-tracking its lead drug, bexmarilimab, which has shown huge promise in treating a type of rare blood cancer. The move follows promising data from the phase I trials involving patients with myelodysplastic syndrome (MDS) who were unresponsive to a class of drugs called hypomethylating agents (HMAs). Jalkanen highlighted the company's ongoing phase 2 trial targeting relapsed refractory MDS, emphasising the strategic goal of securing non-dilutive funding and considering future mergers and acquisitions as the drug shows promise. Jalkanen also discussed the potential of the lead drug candidate in treating specific macrophage-driven cancers, indicating an optimistic outlook for the near term, including significant milestones expected in 2024. These milestones include more phase 2 data, expected by late May, and subsequent FDA feedback, pivotal for future planning. The CEO expressed confidence in the company's position and its appeal to investors, especially given the biotech sector's recovery from a period he referred to as a "nuclear winter." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 08, 2024 08:19 AM Eastern Daylight Time

Video
Article thumbnail News Release

Iofina's strategic success: revenue surpasses $50 million, expansion underway

Iofina PLC

Iofina PLC (AIM:IOF, OTC:IOFNF) CEO Dr Tom Becker takes Proactive's Stephen Gunnion through the company's 2023 full-year performance, which marked another record. Iofina achieved its first-ever revenue exceeding $50 million, marking the sixth consecutive year of growth, a roughly 18% increase from the previous year, with EBITDA at $10.8 million. Becker attributed the growth to effective company strategies but noted challenges like increased input costs due to rising prices of chemicals used in their iodine extraction processes. He anticipates these costs will not escalate as sharply moving forward. Despite a slightly lower realised iodine price in 2023 compared to 2022, the market remains strong, particularly driven by demand for X-ray contrast media. Becker expects iodine prices to remain high, projecting stability into 2024. Iofina also reported strong cash generation, enabling significant debt reduction and a net cash position of $1.2 million. This financial health supports their ongoing investments in expanding iodine production, with new plants such as IO#9 operational and IO#10 expected to start in Q3 2024. Future expansions include plans for an IO#11 plant. Becker highlighted the seasonal increase in iodine production, with the second quarter typically seeing more output due to favourable conditions, and projected an overall increase in 2024 production. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 08, 2024 08:16 AM Eastern Daylight Time

Video
Article thumbnail News Release

ANGLE announces second assay with AstraZeneca as it deepens relationship with pharma giant

ANGLE PLC

ANGLE PLC chief executive Andrew Newland joins Proactive's Stephen Gunnion with details of a supplier agreement with AstraZeneca PLC to develop an androgen receptor (AR) detection assay to enhance prostate cancer studies. With a contract value of £550,000, the project is scheduled for completion in the first quarter of next year. Newland said the agreement is an extension of a prior arrangement to develop a methodology for detecting CTC micronuclei and will use ANGLE's innovative Parsortix system. Successful development of this AR assay is expected to bolster the use of the Parsortix system in clinical oncology, particularly for assessing the efficacy of prostate cancer therapies. The discussion also touched upon the potential benefits of this development for ANGLE, suggesting it might significantly enhance the company's operations and market position. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 08, 2024 08:12 AM Eastern Daylight Time

Video
12345 ... 3544